MX2019007542A - Proceso para la preparación de derivados de 7h-pirrolo [2, 3-d] pirimidina y sus intermedios sintéticos. - Google Patents
Proceso para la preparación de derivados de 7h-pirrolo [2, 3-d] pirimidina y sus intermedios sintéticos.Info
- Publication number
- MX2019007542A MX2019007542A MX2019007542A MX2019007542A MX2019007542A MX 2019007542 A MX2019007542 A MX 2019007542A MX 2019007542 A MX2019007542 A MX 2019007542A MX 2019007542 A MX2019007542 A MX 2019007542A MX 2019007542 A MX2019007542 A MX 2019007542A
- Authority
- MX
- Mexico
- Prior art keywords
- producing
- pyrrolo
- same
- pyrimidine derivative
- synthetic intermediate
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- IRAIXRXGRCCERF-JSGCOSHPSA-N (3S,4R)-1-benzyl-3-methyl-1,7-diazaspiro[3.4]octane Chemical compound C(C1=CC=CC=C1)N1C[C@@H]([C@]11CNCC1)C IRAIXRXGRCCERF-JSGCOSHPSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016247607 | 2016-12-21 | ||
| PCT/JP2017/045729 WO2018117152A1 (ja) | 2016-12-21 | 2017-12-20 | ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその合成中間体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007542A true MX2019007542A (es) | 2019-11-18 |
Family
ID=62627423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007542A MX2019007542A (es) | 2016-12-21 | 2017-12-20 | Proceso para la preparación de derivados de 7h-pirrolo [2, 3-d] pirimidina y sus intermedios sintéticos. |
| MX2024005335A MX2024005335A (es) | 2016-12-21 | 2019-06-21 | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005335A MX2024005335A (es) | 2016-12-21 | 2019-06-21 | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11673900B2 (enExample) |
| EP (2) | EP4793278A2 (enExample) |
| JP (2) | JP6434678B2 (enExample) |
| KR (1) | KR102546513B1 (enExample) |
| CN (2) | CN117865992A (enExample) |
| AU (2) | AU2017384317C1 (enExample) |
| BR (1) | BR112019012688A2 (enExample) |
| CA (1) | CA3047891A1 (enExample) |
| ES (1) | ES3068086T3 (enExample) |
| IL (2) | IL288080B2 (enExample) |
| MX (2) | MX2019007542A (enExample) |
| PL (1) | PL3560932T3 (enExample) |
| TW (2) | TWI816651B (enExample) |
| WO (1) | WO2018117152A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017026173A2 (pt) | 2015-07-07 | 2018-08-14 | Japan Tobacco, Inc. | Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo |
| PL3560932T3 (pl) | 2016-12-21 | 2026-06-29 | Japan Tobacco Inc. | Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich |
| CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
| CN111560021B (zh) * | 2020-06-30 | 2023-05-26 | 上海鲲博玖瑞医药科技发展有限公司 | 一种德高替尼中间体及其制备方法 |
| CN111574540B (zh) * | 2020-06-30 | 2023-08-29 | 云南华派医药科技有限公司 | 一种德高替尼的制备方法 |
| JP2026509302A (ja) | 2023-03-17 | 2026-03-17 | レオ ファーマ アクティーゼルスカブ | 中等症ないし重症の慢性手湿疹を有する患者における慢性手湿疹を処置する方法 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662960B2 (en) | 2001-04-26 | 2010-02-16 | Choongwae Pharma Corporation | Beta-strand mimetics and method relating thereto |
| EP1646633B1 (en) * | 2003-05-30 | 2009-04-15 | Choongwae Pharma Corporation | Beta-strand mimetics |
| US7230119B2 (en) | 2004-08-25 | 2007-06-12 | Biocryst Pharmaceuticals, Inc. | Process for the preparation of substituted pyrrolidine derivatives and intermediates |
| WO2008036755A1 (en) | 2006-09-22 | 2008-03-27 | Janssen Pharmaceutica N.V. | Spiro benzazepines used as vasopressin antagonists |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| SG191291A1 (en) | 2011-01-19 | 2013-07-31 | Galapagos Nv | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases |
| CN103570601B (zh) | 2012-07-20 | 2016-03-30 | 重庆博腾制药科技股份有限公司 | 一种光学活性药物中间体的制备方法 |
| HUE034210T2 (hu) | 2013-03-05 | 2018-02-28 | Theravance Biopharma R&D Ip Llc | Neprilizininhibitorok |
| JP6500634B2 (ja) * | 2015-06-24 | 2019-04-17 | 株式会社Ihi | 溶接装置及び溶接方法 |
| BR112017026173A2 (pt) * | 2015-07-07 | 2018-08-14 | Japan Tobacco, Inc. | Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo |
| TWI822666B (zh) * | 2016-12-21 | 2023-11-21 | 日商日本煙草產業股份有限公司 | Ｊａｎｕｓ激酶抑制劑之結晶型 |
| PL3560932T3 (pl) | 2016-12-21 | 2026-06-29 | Japan Tobacco Inc. | Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich |
-
2017
- 2017-12-20 PL PL17885424.6T patent/PL3560932T3/pl unknown
- 2017-12-20 CN CN202410021834.4A patent/CN117865992A/zh active Pending
- 2017-12-20 EP EP26163662.5A patent/EP4793278A2/en active Pending
- 2017-12-20 KR KR1020197020824A patent/KR102546513B1/ko active Active
- 2017-12-20 US US16/470,888 patent/US11673900B2/en active Active
- 2017-12-20 BR BR112019012688-0A patent/BR112019012688A2/pt active Search and Examination
- 2017-12-20 WO PCT/JP2017/045729 patent/WO2018117152A1/ja not_active Ceased
- 2017-12-20 AU AU2017384317A patent/AU2017384317C1/en active Active
- 2017-12-20 TW TW106144830A patent/TWI816651B/zh active
- 2017-12-20 ES ES17885424T patent/ES3068086T3/es active Active
- 2017-12-20 CN CN201780086625.6A patent/CN110300756B/zh active Active
- 2017-12-20 MX MX2019007542A patent/MX2019007542A/es unknown
- 2017-12-20 JP JP2018518551A patent/JP6434678B2/ja active Active
- 2017-12-20 EP EP17885424.6A patent/EP3560932B1/en active Active
- 2017-12-20 CA CA3047891A patent/CA3047891A1/en active Pending
- 2017-12-20 TW TW112133483A patent/TWI854815B/zh active
- 2017-12-20 IL IL288080A patent/IL288080B2/en unknown
-
2018
- 2018-09-28 JP JP2018185491A patent/JP7098496B2/ja active Active
-
2019
- 2019-06-16 IL IL267385A patent/IL267385B2/en unknown
- 2019-06-21 MX MX2024005335A patent/MX2024005335A/es unknown
-
2022
- 2022-05-24 AU AU2022203506A patent/AU2022203506B2/en active Active
-
2023
- 2023-04-19 US US18/136,661 patent/US12195481B2/en active Active
-
2024
- 2024-11-26 US US18/960,075 patent/US20250084106A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005335A (es) | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. | |
| MX2017016772A (es) | Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. | |
| PH12019501355A1 (en) | Small molecule inhibitors of the jak family of kinases | |
| CL2019000942A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| PH12019501254A1 (en) | Small molecule inhibitors of the jak family of kinases | |
| PH12020500201A1 (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| WO2016063294A3 (en) | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof | |
| PH12018500944A1 (en) | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND | |
| MX385576B (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2 | |
| MX2016007371A (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| MX2010009458A (es) | Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos. | |
| MX386181B (es) | Formas cristalinas de un inhibidor de quinasa janus | |
| AU2017319080A1 (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| MX2017003980A (es) | Nueva sintesis quiral de n-acil-(3-sustituidas)-(8-sustituidas)-5, 6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas. | |
| MX2019007452A (es) | Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos. | |
| MX2018009502A (es) | Metodo para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios. | |
| MX390505B (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2 | |
| MX2019005115A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| NZ740119A (en) | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | |
| CR20200603A (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak | |
| CO2018008253A2 (es) | Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina | |
| MX2016012648A (es) | Proceso para la preparacion de (2s,5r)-6-(benciloxi)-7-oxo-1,6-dia zabiciclo[3.2.1]octano-2-carboxilato de sodio. | |
| MX2019002627A (es) | Compuestos de 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de uso del mismo. | |
| EP4257205A3 (en) | Treatment of hand eczema | |
| ZA201801722B (en) | Treatment of alopecia areata |